Eli Lilly, Camurus in major deal to develop obesity, diabetes drugs

Posted on by wpadmin
unrecognizable overweight mature woman holding in her hand a syringe of semaglutide injectable medication for medical treatment of obesity

David Petrus Ibars/iStock via Getty Images

  • Eli Lilly (NYSE:LLY) has signed a licensing and development agreement with Camurus to develop long-acting incretin products for conditions such as obesity, diabetes, and other metabolic diseases based on the latter’s FluidCrystal technology.
  • The deal allows Lilly to develop up

Leave a Reply

Your email address will not be published. Required fields are marked *